Patents Assigned to Parion Sciences, Inc.
  • Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
    Patent number: 9957238
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: May 1, 2018
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
    Publication number: 20180104241
    Abstract: A very stable, selective and nrenally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
    Type: Application
    Filed: December 15, 2017
    Publication date: April 19, 2018
    Applicant: PARION SCIENCES, INC.
    Inventor: Michael JOHNSON
  • SODIUM CHANNEL BLOCKERS FOR SKIN DISORDERS
    Publication number: 20180092915
    Abstract: Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.
    Type: Application
    Filed: December 6, 2017
    Publication date: April 5, 2018
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
  • Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases
    Patent number: 9878988
    Abstract: Sodium channel blockers represented by the formula: are provided where the structural variables are defined herein. The invention also includes a variety of compositions, combinations and methods of treatment using these inventive sodium channel blockers.
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: January 30, 2018
    Assignee: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
  • Stable sodium channel blockers
    Patent number: 9856224
    Abstract: A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
    Type: Grant
    Filed: January 30, 2017
    Date of Patent: January 2, 2018
    Assignee: PARION SCIENCES, INC.
    Inventor: Michael R. Johnson
  • Sodium channel blockers for skin disorders
    Patent number: 9849129
    Abstract: Provided are methods of treating a variety of disorders of the skin with inhibitors of the epithelial sodium channel (ENaC). The inhibitors are represented by formula (I)-(IV): where R is defined herein.
    Type: Grant
    Filed: February 18, 2016
    Date of Patent: December 26, 2017
    Assignee: PARION SCIENCES, INC.
    Inventors: Michael Ross Johnson, William Robert Thelin, Richard C. Boucher
  • 3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDS
    Publication number: 20170362187
    Abstract: The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.
    Type: Application
    Filed: June 29, 2017
    Publication date: December 21, 2017
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • 3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL) CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE
    Publication number: 20170334864
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Application
    Filed: March 1, 2017
    Publication date: November 23, 2017
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL SODIUM CHANNEL BLOCKING ACTIVITY
    Publication number: 20170327472
    Abstract: This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.
    Type: Application
    Filed: March 7, 2017
    Publication date: November 16, 2017
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDS
    Publication number: 20170305868
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Application
    Filed: March 1, 2017
    Publication date: October 26, 2017
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITY
    Publication number: 20170281620
    Abstract: A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
    Type: Application
    Filed: April 12, 2017
    Publication date: October 5, 2017
    Applicant: PARION SCIENCES, INC.
    Inventor: Michael Ross JOHNSON
  • SODIUM CHANNEL BLOCKERS
    Publication number: 20170267650
    Abstract: The present invention relates to sodium channel blockers. The present invention also includes a variety of methods of treatment using these inventive sodium channel blockers.
    Type: Application
    Filed: October 27, 2016
    Publication date: September 21, 2017
    Applicant: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • STABLE SODIUM CHANNEL BLOCKERS
    Publication number: 20170267649
    Abstract: A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
    Type: Application
    Filed: January 30, 2017
    Publication date: September 21, 2017
    Applicant: PARION SCIENCES, INC.
    Inventor: Michael R. JOHNSON
  • 3,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine-2-carboxamide compounds
    Patent number: 9695134
    Abstract: The present invention relates compounds of the formula: or pharmaceutically acceptable salts thereof, useful as sodium channel blockers, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including cystic fibrosis, chronic obstructive pulmonary disease, asthma, bronchiectasis, acute and chronic bronchitis, emphysema, and pneumonia.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 4, 2017
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • INHALED HYPERTONIC SALINE DELIVERED BY A HEATED NASAL CANNULA
    Publication number: 20170151396
    Abstract: The invention described herein is directed to method of treating chronic obstructive pulmonary disease, comprising administering an effective amount of an osmolyte by at least one nasal cannula to a subject in need thereof. Also provided is a nasal cannula system for delivering an osmolyte, comprising a nebulizer and tubing having two ends, where the first end of the tubing is connected to the nebulizer and the second end of the tubing is tapered to fit in the nostril of a subject.
    Type: Application
    Filed: August 8, 2016
    Publication date: June 1, 2017
    Applicant: Parion Sciences, Inc.
    Inventors: Richard C. BOUCHER, Michael Ross JOHNSON
  • Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activity
    Patent number: 9655896
    Abstract: A very stable, selective and renally safe sodium channel blocker represented by the formula: The invention also includes a variety of compositions, combinations and methods of treatment using this inventive sodium channel blocker.
    Type: Grant
    Filed: January 12, 2015
    Date of Patent: May 23, 2017
    Assignee: PARION SCIENCES, INC.
    Inventor: Michael Ross Johnson
  • Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
    Patent number: 9593084
    Abstract: This invention provides compounds of the formula I: and their pharmaceutically acceptable salts, useful as sodium channel blockers, compositions containing the same, therapeutic methods and uses for the same and processes for preparing the same.
    Type: Grant
    Filed: December 13, 2013
    Date of Patent: March 14, 2017
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyrazine-2-carboxamide
    Patent number: 9586910
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Grant
    Filed: December 18, 2013
    Date of Patent: March 7, 2017
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compounds
    Patent number: 9586911
    Abstract: The present invention relates to the compound of the formula: or pharmaceutically acceptable salts thereof, as well as compositions containing the same, processes for the preparation of the same, and therapeutic methods of use therefore in promoting hydration of mucosal surfaces and the treatment of diseases including chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute and chronic bronchitis, cystic fibrosis, emphysema, and pneumonia.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: March 7, 2017
    Assignee: Parion Sciences, Inc.
    Inventor: Michael R. Johnson
  • NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTS
    Publication number: 20160318861
    Abstract: Provided are mucolytic compounds that are more effective, and/or absorbed less rapidly from mucosal surfaces, and/or are better tolerated as compared to N-acetylcysteine (NAC) and DTT. The compounds are represented by compounds of Formula I which embrace structures (Ia)-(Ib): where the structural variables are as defined herein.
    Type: Application
    Filed: May 2, 2016
    Publication date: November 3, 2016
    Applicant: PARION SCIENCES, INC.
    Inventors: Michael Ross JOHNSON, William R. Thelin